DMXAA

SKU: orb1300915

Featured

Description

Vadimezan (DMXAA) is a murine STING agonist and vascular disrupting agent with antitumor activity. It selectively disrupts tumor blood flow and induces type I interferon, making it a valuable tool for studying cancer immunotherapy and vascular biology in both in vitro and in vivo models.

Research Area

Cardiovascular Research, Immunology & Inflammation

Images & Validation

−

Key Properties

−

CAS Number	117570-53-3
MW	282.29
Purity	>98%
Formula	C₁₇H₁₄O₄
SMILES	Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C
Target	STING
Solubility	Soluble in DMSO (up to 5 mg/ml) or in DMF (up to 14 mg/ml with warming)

Bioactivity

−

Target IC50	DT diaphorase:20 μM (Ki)\|BeWo cells:> 100 μM\|LY3 cells:165 μM\|LY1 cells:177 μM\|Bel-7402 cells:> 100 μM\|COLO 320 cells:39.5 μM\|BGC-823 cells:> 100 μM\|HeLa cells:> 100 μM\|A549 cells:> 100 μM\|HepG2 cells:100.2 μM Read more...
In Vivo	METHODS: To assay antitumor activity in vivo, Vadimezan (20 mg/kg) and BMS1166 (250 µg/mL) were injected intraperitoneally into Balb/c nude mice bearing DLBCL tumor LY1 once daily for eight days. RESULTS: Vadimezan and BMS1166 acted at effective concentrations. The combination treatment significantly inhibited the growth of GCB-like DLBCL cells compared to monotherapy. METHODS: To assay antitumor activity in vivo, Vadimezan (25,5,5,25 mg/kg; 25,0,0,25 mg/kg; 25,25,25,25 mg/kg) was administered intraperitoneally every three days to C57BL/6J mice bearing mouse mesothelioma AE17 for four doses. RESULTS: In group 1, 2/4 mice were cured, of which 2/4 showed long-term survival, but toxicity problems were observed. A better, less toxic response was observed in Group 2, with all four mice cured and showing long-term survival. In group 3, only 1 mouse was cured, but none showed long-term survival, possibly due to associated toxicity issues. Read more...
In Vitro	METHODS: DLBCL cells LY1 and LY3 were treated with Vadimezan (0-300 µM) for 24 h. Cell viability was measured by CCK-8 assay. RESULTS: Vadimezan treatment decreased the viability of DLBCL cells in a dose-dependent manner, with IC50s of 177 μM and 165 μM for LY1 and LY3, respectively. METHODS: Human lung cancer cells A549 were treated with Vadimezan (0.1-1 µM) for 24 h. The expression levels of target proteins were detected by Western Blot. RESULTS: Vadimezan induced a significant increase in the cytoplasmic level of cytochrome c and the activation of caspase 3, which ultimately led to apoptosis and death of A549 cells. Read more...
Cell Research	DLD-1 human colon carcinoma and H460 human non-small cell lung carcinoma cells are routinely maintained as monolayer cultures in RPMI 1640 culture medium supplemented with foetal calf serum (10%), sodium pyruvate (2 mM), penicillin/streptomycin (50 IU mL 1/50 μg mL-1) and l-glutamine (2 mM). Chemosensitivity is assessed using the MTT assay and all assays are performed under aerobic conditions. Briefly, cells are plated into each well of a 96-well culture plate and incubated overnight in an atmosphere containing 5% CO2. Culture medium is completely removed from each well and replaced with medium containing a range of drug concentrations. In the case of menadione alone, the duration of drug exposure is 1 hour, after which the cells are washed twice with Hanks' balanced salt solution prior to the addition of 200 μL fresh RPMI 1640 medium to each well of the plate. In the case of DMXAA alone, the duration of drug exposure is 3 hours. Following a four-day incubation, cell survival is determined using the MTT assay. For combinations of DMXAA with menadione, cells are initially set up and a non-toxic (>95% cell survival) concentration of DMXAA is selected. Cells are then initially exposed to DMXAA (2 mM) for a period of 2 hours, following which the medium is removed and replaced with medium containing the inhibitor (DMXAA at a constant concentration of 2 mM) and menadione (at a range of drug concentrations). Following a further 7-hour incubation, cells are washed twice with Hanks' balanced salt solution prior to the addition of growth medium.(Only for Reference) Read more...

Storage & Handling

−

Storage	RT
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

ASA404; Vadimezan

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Compound Identifiers

PubChem CID

123964 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

DMXAA (orb1300915)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

CAS Number:	1507367-51-2
MW:	659.4
Formula:	C₂₀H₂₃N₉O₁₃P₂

Purity:	>98% (HPLC)
CAS Number:	117570-53-3
MW:	282.2906
Formula:	C₁₇H₁₄O₄

Purity:	>98% (HPLC)
CAS Number:	555-60-2
MW:	204.62
Formula:	C₉H₅ClN₄

DMXAA

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products

cAIMP [orb2815696]

DMXAA [orb1226875]

CCCP [orb1222043]

Quality Guarantee

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

DMXAA (orb1300915)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors